Ireland tackles vCJD (variant Creutzfeldt Jakob disease) with surgery and blood policies
This article was originally published in Clinica
Executive Summary
Ireland is the latest country to defer blood donors who have lived in the UK during the height of the TSE/vCJD crisis, in order to minimise the risk of infection by transfusion. New clinical guidelines, including surgical and other techniques aimed at reducing blood loss, are among the strategies being implemented to back the measure.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.